封面
市场调查报告书
商品编码
1441309

全球缓释性辅料市场规模、份额、成长分析(按产品类型、给药途径和技术)- 产业预测,2023-2030 年

Global Sustained Release Excipients Market Size, Share, Growth Analysis, By Product type(Gelatin, Polymers), By Route of Administration(Oral, Intramuscular), By Technology(Targeted Delivery, Microencapsulation) - Industry Forecast 2023-2030

出版日期: | 出版商: SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格
简介目录

2022年全球缓释性辅料市场规模为12.6亿美元,从2023年的13.7亿美元成长到2031年的26亿美元,在预测期间(2024-2031年)预计复合年增长率为8.4%。

全球缓释性辅料市场正在稳步成长,预计未来将继续扩大。缓释性辅料是製剂的重要组成部分,旨在在较长时间内逐渐释放活性成分,从而提高患者的依从性和治疗结果。该市场受到多种因素的推动,例如慢性病的流行、对创新药物输送系统的需求不断增加以及药物研发投资的增加。此外,人口老化以及由此导致的长效药物需求激增进一步推动了市场成长。缓释性利用多种赋形剂,包括聚合物、脂质和水凝胶。乙基纤维素、羟丙基甲基纤维素 (HPMC) 和聚乳酸乙醇酸 (PLGA) 等聚合物因其生物相容性、控制释放特性和配方的多功能性而特别引人注目。

目录

执行摘要

  • 市场概况
  • 繁荣与衰落

调查方法

  • 资讯采购
  • 次要和主要资料来源
  • 市场规模估算
  • 市场假设与限制

母市场分析

  • 市场概况
  • 市场规模
  • 市场动态
    • 促进因素
    • 机会
    • 抑制因素
    • 任务

主要市场考察

  • 技术分析
  • 价格分析
  • 供应链分析
  • 价值链分析
  • 市场生态系统
  • 智慧财产权分析
  • 贸易分析
  • Start-Ups分析
  • 原料分析
  • 创新矩阵
  • 研发线产品分析
  • 总体经济指标
  • 主要投资分析
  • 关键成功因素
  • 竞争程度

市场动态及前景

  • 市场动态
    • 促进因素
    • 机会
    • 抑制因素
    • 任务
  • 监管环境
  • 波特的分析
  • 对未来中断的特殊考虑

全球缓释性辅料市场:依产品类型

  • 市场概况
  • 明胶
  • 聚合物
  • 矿物
  • 其他的

全球缓释性辅料市场:依给药途径

  • 市场概况
  • 口服
  • 肌肉注射
  • 皮下的
  • 经皮的
  • 静脉
  • 其他给药途径

全球缓释性辅料市场:依技术分类

  • 市场概况
  • 标靶化的介绍
  • 微胶囊化
  • 阿尔斯特技术
  • 其他技术

全球缓释性辅料市场规模(按地区)

  • 市场概况
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地区
  • 中东/非洲
    • 海湾合作委员会国家
    • 南非
    • 其他中东/非洲地区

竞争格局

  • 前5名企业对比
  • 主要企业市场定位(2021年)
  • 主要市场参与者所采取的策略
  • 关键成功策略
  • 近期市集活动
  • 主要企业市场占有率(2021年)

主要企业简介

  • 艾尔建公司(爱尔兰)
  • 阿斯特捷利康(英国)
  • 葛兰素史克公司(英国)
  • 梅恩製药集团有限公司(澳洲)
  • 迈兰 NV(美国)
  • 诺华公司(瑞士)
  • 辉瑞公司(美国)
  • Salix 製药公司(美国)
  • 太阳製药工业有限公司(印度)
  • 罗氏控股公司(瑞士)
  • 赛诺菲(法国)
  • 强生公司(美国)
  • 礼来公司(美国)
  • 默克公司(美国)
  • 梯瓦製药工业股份有限公司(以色列)
  • 艾伯维公司(美国)
  • 百时美施贵宝(美国)
  • 吉利德科学公司(美国)
  • 拜耳公司(德国)
  • 武田药品工业株式会社(日本)
简介目录
Product Code: SQMIG35I2231

Global Sustained Release Excipients Market size was valued at USD 1.26 billion in 2022 and is poised to grow from USD 1.37 billion in 2023 to USD 2.60 billion by 2031, growing at a CAGR of 8.4% in the forecast period (2024-2031).

The global sustained release excipients market was experiencing steady growth and is expected to continue expanding in the coming years. Sustained release excipients are crucial components in drug formulations designed to release active ingredients gradually over an extended period, thereby improving patient compliance and therapeutic outcomes. The market is driven by several factors, including the rising prevalence of chronic diseases, increasing demand for innovative drug delivery systems, and growing investment in pharmaceutical research and development. Additionally, the aging population and the subsequent surge in demand for long-acting medications further fuel market growth. Various excipients are utilized in sustained release formulations, including polymers, lipids, and hydrogels, among others. Polymers such as ethylcellulose, hydroxypropyl methylcellulose (HPMC), and poly (lactic-co-glycolic acid) (PLGA) are particularly prominent due to their biocompatibility, controlled release properties, and versatility in formulation.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Sustained Release Excipients Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Sustained Release Excipients Market Segmental Analysis

Based on product type the market is segmented as Gelatin, Polymers, Minerals, Sugars, and Others. On the basis of route of administration the market is segmented as Oral, Intramuscular, Subcutaneous, Transdermal, Intravenous, and Other Routes of Administration. Based on technology, it is segregated into Targeted Delivery, Microencapsulation, Wurster Technique, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Sustained Release Excipients Market

One key market driver propelling the growth of the sustained release excipients market is the rising geriatric population worldwide. With aging populations, there is a higher incidence of chronic diseases such as cardiovascular disorders, diabetes, and neurological conditions, necessitating long-term medication regimens. Sustained release formulations offer advantages in terms of improved patient compliance, reduced side effects, and enhanced therapeutic outcomes by maintaining consistent drug levels in the body over an extended period. Consequently, pharmaceutical manufacturers are increasingly incorporating sustained release excipients into their formulations to cater to the needs of the aging population, thereby driving market expansion.

Restraints in the Global Sustained Release Excipients Market

However, despite the promising growth prospects, the sustained release excipients market faces certain restraints that may hinder its growth trajectory. One notable challenge is the stringent regulatory requirements governing the approval and commercialization of sustained release formulations. Regulatory agencies impose rigorous standards for the safety, efficacy, and quality of pharmaceutical products, including those utilizing sustained release technologies. Meeting these regulatory guidelines demands substantial investments in research, development, and manufacturing capabilities, which can pose barriers to entry for smaller players and startups. Moreover, delays in regulatory approvals can prolong the time to market, impacting product launch timelines and revenue generation potential for companies operating in this space.

Market Trends of the Global Sustained Release Excipients Market

In terms of trends, there is a growing emphasis on the development of innovative sustained release excipients to address evolving market needs and enhance product performance. Manufacturers are investing in advanced formulation technologies and excipient materials to achieve optimized drug release profiles, improved bioavailability, and enhanced stability of pharmaceutical formulations. Additionally, there is increasing adoption of multifunctional excipients capable of providing additional functionalities such as taste masking, moisture protection, and modified release kinetics. Furthermore, strategic collaborations and partnerships between pharmaceutical companies and excipient suppliers are on the rise to leverage combined expertise and resources for product development and commercialization, thereby driving innovation and market growth in the sustained release excipients segment.

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Regulatory Landscape
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
    • Political Impact
    • Economic Impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Global Sustained Release Excipients Market by Product type

  • Market Overview
  • Gelatin
  • Polymers
  • Minerals
  • Sugars
  • and Others

Global Sustained Release Excipients Market by Route of Administration

  • Market Overview
  • Oral
  • Intramuscular
  • Subcutaneous
  • Transdermal
  • Intravenous
  • and Other Routes of Administration

Global Sustained Release Excipients Market by Technology

  • Market Overview
  • Targeted Delivery
  • Microencapsulation
  • Wurster Technique
  • and Other Technologies

Global Sustained Release Excipients Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
    • By Development
    • By Company
    • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021

Key Company Profiles

  • Allergan PLC (Ireland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline PLC (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mayne Pharma Group Limited (Australia)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mylan NV (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Salix Pharmaceuticals (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sun Pharmaceutical Industries Ltd (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Roche Holdings AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical Industries Ltd (Israel)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol-Myers Squibb (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gilead Sciences, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company Limited (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments